ORIGINAL RESEARCH

Determinants and consequences of insulin initiation for type 2 diabetes in France: analysis of the National Health and Wellness Survey

Gérard Reach[1]
Véronique Le Pautremat[2]
Shaloo Gupta[3]

[1]Department of Endocrinology,
Diabetes, and Metabolic Diseases,
Avicenne Hospital APHP, and EA
3412, CRNH-IdF, Paris 13 University,
Sorbonnne Paris Cité, Bobigny, France;
[2]Kantar Health, Paris, France; [3]Kantar
Health, Princeton, NJ, USA

Background: The aim of the study was to identify the intrinsic patient characteristics and extrinsic environmental factors predicting prescription and use and, more specifically, early initiation (up to 5 years of disease duration) of insulin for type 2 diabetes in France. A secondary objective was to evaluate the impact of insulin therapy on mental and physical quality of life and patient adherence.

Methods: The data used in this study were derived from the 2008, 2010, and 2011 France National Health and Wellness Survey. This survey is an annual, cross-sectional, self-administered, Internet-based questionnaire among a nationwide representative sample of adults (aged 18 years or older). Of the total of 45,958 persons recruited in France, 1,933 respondents (deduped) were identified as diagnosed with type 2 diabetes. All unique respondents from the three waves, currently using insulin or oral bitherapy or tritherapy at the time of assessment, were included in this analysis.

Results: Early (versus late) initiation of insulin therapy was 9.9 times more likely to be prescribed by an endocrinologist or diabetologist than by a primary care physician ($P < 0.0001$). Younger age at diagnosis and current smoking habits were significant predictors of early (versus late) insulin initiation (odds ratio [OR] 1.031, 95% confidence interval [CI] 1.005–1.059, $P = 0.0196$, and OR 2.537, 95% CI 1.165–5.524, $P = 0.0191$, respectively). Patients with a yearly income ≥€50,000 were less likely to be put on insulin early ($P = 0.0399$). A link between insulin prescription and complications was shown only in univariate analysis. Mental quality of life was lower in patients on early (versus late) insulin, but only in patients with diabetes-related complications. Insulin users (versus oral bitherapy or tritherapy users) had 3.0 times greater odds of being adherent than uncontrolled oral bitherapy or tritherapy users (OR 2.983, 95% CI 1.37–6.495, $P = 0.0059$).

Conclusion: This study confirms the role of specialists in early initiation of insulin, and the data presented herein reflect the fact that early initiation is more frequent in younger patients, patients with diabetes-related complications, and current smokers, and less frequent in patients with a higher income. Moreover, we observed that being treated with insulin was not associated with deterioration in quality of life, and insulin-treated patients were more often adherent than uncontrolled oral bitherapy or tritherapy users. These data suggest that doctors' concerns about patient adherence and detrimental effects on quality of life should not be a barrier to their decision regarding early initiation of insulin therapy. Due to the nature of this cross-sectional survey (eg, inability to assess treatment flow), further research is needed to confirm its findings.

Keywords: type 2 diabetes, early insulin initiation, quality of life, adherence, psychological insulin resistance, clinical inertia

Correspondence: Gérard Reach
Service d'Endocrinologie, Diabétologie,
Maladies Métaboliques, Hôpital Avicenne
APHP, 125 route de Stalingrad,
93000 Bobigny, France
Tel +331 4895 5158
Fax +331 4895 5560
Email gerard.reach@avc.aphp.fr

Introduction

The prevalence of type 2 diabetes is increasing worldwide, with the number of affected individuals expected to double by 2050.[1] Diabetes is a leading cause of kidney failure,

blindness, leg amputation, and myocardial infarction. There is evidence that early control of blood glucose can help prevent these diabetes-related complications.[2] Current treatment is based on a stepwise approach starting with changes in lifestyle and progressively introducing oral antidiabetic agents, with the aim of maintaining glycated hemoglobin (HbA$_{1c}$) levels below a defined target. This target is defined according to the patient's characteristics.[3–5] In the current paradigm, insulin is usually considered to be the last step in treatment intensification.

Prescribing insulin at later stages of type 2 diabetes disease progression has recently been challenged, arguing that a delay in insulin initiation may affect the patient's long-term prognosis. Indeed, it is well known that elevated fasting plasma glucose levels are primarily due to an increase in hepatic glucose production, secondary to an insufficient endogenous insulin secretion needed to overcome insulin resistance.[6] Furthermore, there is a well documented decline in insulin secretion due to beta cell exhaustion, and it has been suggested that early use of insulin may suppress inflammation and glucolipotoxicity, which results in autoaggravation of the disease.[7]

However, early introduction of insulin may represent a challenge with regard to the well known "psychological insulin resistance" status affecting both patients and doctors. This results in delayed insulin prescription when it would be appropriate according to current guidelines. Psychological insulin resistance,[8] which represents a typical case of clinical inertia,[9–14] may be due in part, on the side of the doctor, to the supposed effect of insulin treatment on patients' quality of life which may hinder future adherence.[15–19] On the other hand, nonadherence to long-term therapies also represents a barrier to the efficiency of care,[20–22] even if it seems that doctors' clinical inertia is actually more frequent than patient nonadherence.[23]

In this context, the objective of this study using data from the National Health and Wellness Survey (NHWS) carried out in France was to identify the intrinsic and extrinsic determinants of insulin prescription, and more specifically of early insulin initiation (being defined as 5 years or less following diagnosis) in type 2 diabetes, and to evaluate the impact of insulin therapy on mental and physical quality of life and patient adherence.

Materials and methods
National Health and Wellness Survey sample
The study sample and data were taken from the 2008, 2010, and 2011 waves (2008, n = 15,457; 2010, n = 15,501; 2011,

n = 15,000) of the French NHWS. The NHWS is an annual Internet-based questionnaire developed by Kantar Health and the Ailment Panel of Lightspeed Research. It is a cross-sectional study of subjects aged 18 years or older, conducted with a strictly identical methodology for the 3 years (2008, 2010, and 2011). Only a small proportion of individuals from the sample were common between waves (approximately one in five) and data from recent participation were retained.

The primary objective of the NHWS is to provide a comprehensive database of epidemiological and treatment information, health care attitudes, behaviors, demographic and disease characteristics, and health-related outcomes. The 2011, 2010, and 2008 surveys employ a stratified random sample (with both sex and age group quotas), in order to replicate the demographic composition of each of the population of each individual country. Representation of NHWS data has been validated against reliable sources, including government agencies' health statistics and nonaffiliated third parties. Results are projected to reflect the total population in each country using known population characteristics. In France, data are weighted by sex and age using the United States Bureau of the Census and Organization for Economic Cooperation and Development.

A self-administered questionnaire is completed by a sample population identified through a web-based consumer panel. All data from the NHWS are self-reported by participating respondents. All respondents received and agreed with the informed consent form provided, and the study was approved by the Essex Institutional Review Board (Lebanon, NJ, USA). Of the total 45,958 persons recruited (three waves deduped study sample), 1,933 respondents were identified as reporting a physician diagnosis of type 2 diabetes, comprising 591 from the 2008 wave, 649 from 2010, and 693 from 2011 (respectively 3.8%, 4.2%, and 4.3% of the general population of adults). All unique respondents diagnosed with type 2 diabetes currently using insulin or oral bitherapy or tritherapy at the time of assessment were included (n = 713, see Table 1); this choice was justified by the fact that, both according to current guidelines and as a result of doctors' and patients' psychological insulin resistance, patients treated with dual therapy or tritherapy have a greater likelihood of being switched to insulin than those treated with monotherapy.

Measures and survey instruments
Independent variables
We first compared all patients on bitherapy or tritherapy (n = 443) and all insulin users (n = 270). Second, we compared early and late initiation of insulin: based on calcula-

Table 1 Sample sizes

Groups (deduped)*	Sample size (n)
All oral bitherapy or tritherapy users	443
Uncontrolled** bitherapy or tritherapy users	105
without any complications	360
All insulin users	270
With:	
Early insulin initiation (5 years or less)	143
Early insulin initiation (5 years or less) without any complication^	77
Short duration of insulin (5 years or less)	141
Short duration of insulin (5 years or less) without any complication^	94

Notes: *Users of glucagon-like peptide-1 were excluded from this analysis due to their small sample size (n = 46); **uncontrolled users were defined as having an HbA_{1c} >7% or, if they were missing their HbA_{1c} level their fasting plasma glucose was >130 mg/dL; ^a complication was defined as reporting having myocardial infarction, stroke, transient ischemic attack, diabetic retinopathy, diabetic peripheral neuropathy, kidney damage, end organ damage (only collected in 2010 and 2011), or foot ulcer.

tion of the number of years between diagnosis of type 2 diabetes and initiation of insulin, with early insulin defined as 5 years or less (n = 143). The control group (n = 124) consisted of those patients who were prescribed insulin later. Third, another independent variable of interest was the duration of insulin use, using a median split of the number of years using insulin, ie, 5 years or less versus 6 years or more (Table 1).

Covariates

Regardless of how early initiation is defined, great care must be taken in isolating the effect of early initiation or beginning insulin on health outcomes, given the cross-sectional, observational nature of the NHWS. Insulin can be initiated for a variety of reasons as physicians attempt to manage risk in their patients. Irrespective of outcomes, the model included the following predictors: age/age at diagnosis, duration of type 2 diabetes, sex, education, household income, and employment type (see Table 2). The following health information was also included: body mass index, smoking status, alcohol use, exercise habits, diabetes complications experienced, prescribing physician, being afraid of needles, HbA_{1c}, fasting glucose, treatment satisfaction, and Charlson comorbidity index. The Charlson comorbidity index is calculated by weighting the presence of specific comorbidities based on their association with future mortality and summing the results. Models consisting of respondents with uncontrolled type 2 diabetes did not include HbA_{1c} level and fasting glucose as predictors.

Table 2 Definition of covariates

Parameter	Reference
Age/age at diagnosis	–
Duration of type 2 diabetes	
Sex	Male
College degree +	Less than college degree
Income	
€20,000 to <€50,000	<€20,000
≥€50,000	
Decline to answer	
Employed full-time/part-time/ self-employed	Unemployed
Currently drinking alcohol	No current alcohol use
Currently smoking	Not a current smoker
Currently exercising	No current exercise
Body mass index	
Overweight	Normal/underweight
Obese	
Declined	
Charlson comorbidity index	–
Complications experienced	
Macular edema or diabetic retinopathy	Not experienced
Neuropathic pain	
Kidney disease	
Foot or leg ulcer	
Prescribing physician, general practitioner	Specialist
Strongly agree/agree with being afraid of needles	Neutral/disagree/strongly disagree with being afraid of needles
HbA_{1c}	≤7%
>7%	
Unknown	
Fasting glucose	
≥130 mg/dL	≤130 mg/dL
Unknown	
Very/extremely satisfied with diabetes treatment	Less satisfaction with diabetes treatment

Note: Models representing uncontrolled individuals did not include HbA_{1c} levels or fasting glucose as covariates.

Quality of life and medication adherence outcomes

The following measures of quality of life (validated scales) were used in this analysis: physical (PCS) and mental (MCS) component summary scores from the Short Form Survey Instrument Version 2 (SF-12v2). The SF-12v2 is a multipurpose generic measure of health status, consisting of 12 questions designed to assess physical functioning, role limitations due to physical health problems, body pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores for the PCS and MCS rely on norm-based scoring, with higher scores indicating better quality of life. The average score is 50.[24]

Medication adherence was assessed using the Morisky Medication Adherence Scale (MMAS). The MMAS consists of four yes/no questions that assess the general adherence of using prescribed medication.[25] The total score varies from 0 to 4, with lower scores indicating greater adherence; adherence (0) versus nonadherence (1–4) were compared. Medication adherence data was only collected in 2010 and 2011. Therefore, the sample size is smaller compared with the other metrics.

Statistical analyses

Bivariate and multivariate analyses were conducted. Bivariate analyses were used to compare data between patients on insulin versus patients on oral bitherapy or tritherapy, and data between patients starting early insulin versus late insulin. Chi-square tests were used for categorical variables and the t-test was used for continuous variables to determine differences between groups.

The independent variables were used in multivariable analyses to identify differences between two groups on quality of life outcome measures and adherence after adjusting for differences in demographics and patient characteristics. This was achieved by regression modeling (logistic and multivariable linear regressions). For all statistical tests, the applied comparison-wise significance level was a P value < 0.05.

Results

Determinants of insulin prescription
Patients on insulin versus patients on oral bitherapy or tritherapy

The average age of patients on insulin (n = 270) and on oral bitherapy or tritherapy (n = 443) was comparable (59.14 years versus 60.27 years) while 61.48% and 69.98%, respectively, were men ($P = 0.021$). Those on insulin were younger at diagnosis (mean 44.6 years versus 49.5 years, $P < 0.0001$), and the average duration of type 2 diabetes since diagnosis was longer (14.7 years versus 10.75 years, $P < 0.0001$). Socioeconomically, they more likely to have less income (<€20,000/year: 32.59% versus 21.90%, $P = 0.0021$), and were less likely to have a higher level of secondary education (24.44% versus 33.41%, $P = 0.0096$). In terms of clinical characteristics, they were less frequently overweight (31.85% versus 39.95%, $P = 0.0277$), had a higher Charlson comorbidity index (0.6 versus 0.33, $P = 0.0017$), significantly more likelihood of myocardial infarction ($P = 0.0422$), and presented more microvascular and macrovascular complications ($P < 0.0001$). They were more often poorly controlled ($HbA_{1c} > 7\%$: 32.96%

versus 17.61%, $P < 0.0001$). They were more frequently followed up by a prescribing physician who was not a general practitioner (77.78% versus 24.15%, $P < 0.0001$) and were more often aware of their HbA_{1c} level ($P < 0.0001$). Finally, they were significantly more adherent (adherence MMAS = 0: 82.61% versus 72.36%, $P = 0.0066$). We did not observe differences in terms of healthy lifestyle (physical exercise), risk factors (alcohol, smoking), or fear about needles (Table 3).

As shown in Table 4, a logistic regression was run to assess factors that influence insulin use versus oral bitherapy or tritherapy use. The probability of taking insulin was raised if the patient presented the following factors, in decreasing order: retinopathy or macular edema (odds ratio [OR] 3.035, 95% confidence interval [CI] 1.317–6.992, $P = 0.0091$) and neuropathic pain (OR 2.095, 95% CI 1.149–3.822, $P = 0.0159$). On the contrary, patients treated by a specialist had a 12 times greater odds of using insulin (OR 0.083, 95% CI 0.054–0.128, $P < 0.0001$) versus patients followed up by a prescribing general practitioner, and those who had an income ≥€50,000 per annum were less likely to receive insulin (OR 0.26, 95% CI 0.119–0.567, $P = 0.0007$). Finally, older age at diagnosis was associated with less likelihood of being put on insulin (OR 0.974, 95% CI 0.955–0.994, $P = 0.0117$). Overweight and unknown fasting glucose were marginally significant predictors of oral use.

Factors influencing early initiation of insulin

As shown in Table 5, patients were younger in the type 2 diabetes early insulin initiation group (n = 143) than in the type 2 diabetes initiated later with insulin group (n = 124), ie, 56.37 years versus 62.6 years ($P < 0.0001$) and this was confirmed in the younger age group at initiation of insulin (47.42 years versus 56.86 years, respectively, $P < 0.0001$). Fewer males initiated insulin early compared with the late insulin initiation group (55.24% versus 68.55% respectively, $P < 0.025$). Socioeconomically, they had a lower income (<€20,000 per year: 38.46% versus 26.61%, $P = 0.0384$). In terms of lifestyle, they were more likely to smoke (23.08% versus 10.48%, $P = 0.0053$), and reported less controlled type 2 diabetes ($HbA_{1c} > 7\%$, 25.87% versus 41.94%, $P < 0.0057$).

As shown in Table 6, a logistic regression was run to assess factors that influence early initiation of insulin (≤5 years) versus late initiation using a median split (Table 5). Younger age at diagnosis and currently smoking were significant predictors of early insulin initiation (OR 1.031, 95% CI 1.005–1.059, $P = 0.0196$, and OR 2.537, 95% CI 1.165–5.524,

Table 3 Analyzed population: all insulin users versus all users of bitherapy or tritherapy

	All insulin users n = 270		All bi- or tritherapy users n = 443		P-value
	n	%	n	%	
Age (mean, SD)	59.14	10.86	60.27	9.32	0.1554
Age at diagnosis	44.6	11.95	49.53	10.39	<0.0001
Age at insulin initiation	51.61	13.03	–	–	N/A
Years diagnosed	14.66	9.88	10.75	7.61	<0.0001
Sex					
Male	166	61.48%	310	69.98%	0.0213
Female	104	38.52%	133	30.02%	0.0213
Currently employed	76	28.15%	121	27.31%	0.8096
Household income					
<20,000€	88	32.59%	97	21.90%	0.0021
20,000€ to <50,000€	138	51.11%	233	52.60%	0.7006
50,000€ or more	22	8.15%	65	14.67%	0.0061
Decline to answer	22	8.15%	48	10.84%	0.2281
College education	66	24.44%	148	33.41%	0.0096
BMI					
Underweight	0	0.00%	1	0.23%	N/A
Normal weight	40	14.81%	45	10.16%	0.0735
Overweight	86	31.85%	177	39.95%	0.0277
Obese	135	50.00%	209	47.18%	0.4651
Decline to answer	9	3.33%	11	2.48%	0.5197
Health behaviors					
Currently drink	190	70.37%	336	75.85%	0.1126
Currently smoke	47	17.41%	75	16.93%	0.8701
Regularly exercise	141	52.22%	238	53.72%	0.697
Charlson comorbidity index (mean, SD)	0.6	1.33	0.33	0.69	0.0017
Comorbidities					
Depression	36	13.33%	50	11.29%	0.4242
Myocardial infarction	23	8.52%	20	4.51%	0.0422
Stroke	12	4.44%	10	2.26%	0.1294
TIA	4	1.48%	2	0.45%	0.1995
Congestive heart failure	8	2.96%	7	1.58%	0.246
Hypertension	111	41.11%	205	46.28%	0.1771
Angina	27	10.00%	50	11.29%	0.5869
Arrhythmia	13	4.81%	31	7.00%	0.2208
Prescribing physician					
PCP	53	19.63%	334	75.40%	<0.0001
Endocrinologist/diabetologist	210	77.78%	107	24.15%	<0.0001
Nurse practitioner/physician assistant	0	0.00%	0	0.00%	N/A
Other	7	2.59%	2	0.45%	0.0361
Agree/strongly agree to being afraid of needles	24	8.89%	47	10.61%	0.4485
Microvascular complications					
Macular edema	43	15.93%	14	3.16%	<0.0001
Neuropathic pain	53	19.63%	33	7.45%	<0.0001
Kidney damage	28	10.37%	11	2.48%	<0.0001
End organ damage (2010, 2011 only)	14	7.61%	5	1.55%	0.0038
Foot ulcer	14	5.19%	16	3.61%	0.3305
At least one microvascular complication	104	38.52%	64	14.45%	<0.0001
At least one complication (TIA, Stroke, HA or microvascular complication)	119	44.07%	83	18.74%	<0.0001
HbA$_{1c}$ (%)					
HbA$_{1c}$ >7	89	32.96%	78	17.61%	<0.0001
HbA$_{1c}$ (missing)	94	34.81%	228	51.47%	<0.0001

(*Continued*)

Table 3 (*Continued*)

	All insulin users n = 270		All bi- or tritherapy users n = 443		*P*-value
	n	%	n	%	
Fasting glucose (mg/dl)					
Fasting glucose >130	42	15.56%	45	10.16%	0.0409
Fasting glucose (missing)	152	56.30%	311	70.20%	0.0002
Satisfaction with treatment					
Very/extremely satisfied with treatment	149	55.60%	227	51.24%	0.2592
Very/extremely dissatisfied with treatment	40	14.93%	51	11.51%	0.1991
Morisky adherence* (2010, 2011 only)					
Compliant (MMAS = 0)	152	82.61%	233	72.36%	0.0066
Forget to take medication	25	13.59%	80	24.84%	0.0014
Careless about medication	12	6.52%	36	11.18%	0.0667
Stop when feeling better	1	0.54%	5	1.55%	0.2508
Stop when feeling worse	5	2.72%	16	4.97%	0.1876

Notes: *Assessed using the MMAS. The MMAS includes four items ("do you ever forget to take your medicine?"; "are you careless at times about taking your medicine?"; "when you feel better do you sometimes stop taking your medicine?"; and "sometimes if you feel worse when you take your medicine, do you stop taking it?"). All items have a dichotomous yes/no response scale and are summed to form a total score (which varies from 0 to 4, with lower scores indicating greater adherence).
Abbreviations: BMI, body mass index; MMAS, Morisky Medication Adherence Scale; SD, standard deviation; HA, heart attack; TIA, transient ischemic attack; PCP, primary care physician.

P = 0.0191, respectively). Inversely, high income (€20,000–€50,000) was a significant predictor of late insulin initiation (OR 0.452, 95% CI 0.239–0.856, *P* = 0.0148). It should be noted that a currently uncontrolled HbA$_{1c}$ level was a marginally significant predictor of late insulin initiation (OR 0.549, 95% CI 0.28–1.076, *P* = 0.0807).

A logistic regression was also run to assess the factors that influence early insulin initiation versus the subgroup of uncontrolled oral bitherapy or tritherapy users. From Table 6, we can see that high income was also associated with late insulin initiation, with patients receiving an income of ≥€50,000 per annum having lower odds of being put on insulin early (OR 0.26, 95% CI 0.072–0.94, *P* = 0.0399). It should be noted that the odds of early initiation of insulin therapy prescribed by an endocrinologist or diabetologist were 9.9 greater compared with a primary care physician (OR 0.101, 95% CI 0.05–0.204, *P* < 0.0001).

Predictors of control of type 2 diabetes

As shown in Table 7, when comparing controlled patients (all therapies, n = 224) versus uncontrolled (HbA$_{1c}$ <7%) patients (n = 208), those with controlled diabetes were older at diagnosis (48.16 years versus 45.38 years, *P* = 0.0109), were less often treated with insulin (38.84% versus 49.52%, *P* = 0.0254), had macular edema less often (6.25% versus 14.42%, *P* = 0.0055), or at least one microvascular complication (20.09% versus 33.65%, *P* = 0.0015), were very satisfied with treatment more often (65.18% versus 46.63%, *P* < 0.0001), and forgot less often to take their medication (15.87% versus 25.00%, *P* = 0.0411).

A logistic regression was run to assess the factors that influence control of HbA$_{1c}$ (all types of treatment, Table 8). Three factors were associated with controlled diabetes, ie, patient satisfaction with treatment (OR 2.545, 95% CI 1.556–4.16, *P* = 0.0002), a short duration of diabetes (OR

Table 4 Statistically significant factors influencing prescription of insulin: insulin users versus bitherapy or tritherapy users (n = 705)

Parameter	Estimate	OR	95% LCL for OR	95% UCL for OR	SE	Chi-square	*P*-value
Age at diagnosis	−0.026	0.974	0.955	0.994	0.0103	6.3489	0.0117
Income: ≥€50,000	−1.349	0.26	0.119	0.567	0.3987	11.439	0.0007
Income: declined to answer	−0.831	0.436	0.201	0.944	0.3949	4.4294	0.0353
Macular edema or diabetic retinopathy	1.1102	3.035	1.317	6.992	0.4258	6.7983	0.0091
Neuropathic pain	0.7397	2.095	1.149	3.822	0.3067	5.8187	0.0159
Prescribing physician: GP	−2.486	0.083	0.054	0.128	0.2201	127.62	<0.0001

Abbreviations: GP, general practitioner; OR, odds ratio; SE, standard error; LCL, lower confidence limit; UCL, upper confidence limit.

Table 5 Analyzed population: early versus late insulin initiation

	Early insulin initiation (5 years or less) n = 143		Late insulin initiation (6 years or more) n = 124		P-value
	n	%	n	%	
Age (mean, SD)	56.37	11.09	62.6	8.81	<0.0001
Age at diagnosis	45.74	13.52	43.29	9.73	0.0875
Age at insulin initiation	47.42	13.95	56.86	9.41	<0.0001
Sex					
Male	79	55.24%	85	68.55%	0.025
Female	64	44.76%	39	31.45%	0.025
Currently employed	44	30.77%	30	24.19%	0.2295
Household income					
<20,000€	55	38.46%	33	26.61%	0.0384
20,000€ to <50,000€	62	43.36%	73	58.87%	0.0112
50,000€ or more	11	7.69%	11	8.87%	0.7288
Decline to answer	15	10.49%	7	5.65%	0.1435
College education	37	25.87%	28	22.58%	0.5314
BMI					
Underweight	0	0.00%	0	0.00%	N/A
Normal weight	22	15.38%	15	12.10%	0.4358
Overweight	41	28.67%	45	36.29%	0.1864
Obese	74	51.75%	61	49.19%	0.6779
Decline to answer	6	4.20%	3	2.42%	0.4149
Health behaviors					
Currently drink	96	67.13%	92	74.19%	0.2058
Currently smoke	33	23.08%	13	10.48%	0.0053
Regularly exercise	72	50.35%	67	54.03%	0.5489
Charlson comorbidity index (mean, SD)	0.59	1.33	0.62	1.33	0.8712
Comorbidities					
Depression	22	15.38%	13	10.48%	0.232
Myocardial infarction	13	9.09%	10	8.06%	0.7654
Stroke	6	4.20%	6	4.84%	0.8018
TIA	1	0.70%	3	2.42%	0.2677
Congestive heart failure	4	2.80%	4	3.23%	0.8389
Hypertension	64	44.76%	46	37.10%	0.2045
Angina	18	12.59%	9	7.26%	0.1432
Arrhythmia	4	2.80%	9	7.26%	0.1013
Prescribing physician					
PCP	27	18.88%	26	20.97%	0.6716
Endocrinologist/diabetologist	113	79.02%	94	75.81%	0.5327
Nurse practitioner/physician assistant	0	0.00%	0	0.00%	N/A
Other	3	2.10%	4	3.23%	0.5718
Agree/strongly agree to being afraid of needles	14	9.79%	10	8.06%	0.6217
Microvascular complications					
Macular edema	21	14.69%	22	17.74%	0.5013
Neuropathic pain	31	21.68%	22	17.74%	0.4198
Kidney damage	16	11.19%	12	9.68%	0.6871
End organ damage (2010, 2011 only)	7	7.29%	7	8.05%	0.8489
Foot ulcer	9	6.29%	5	4.03%	0.4025
At least one microvascular complication	58	40.56%	46	37.10%	0.5633
At least one complication (TIA, stroke, HA, or microvascular complication)	66	46.15%	53	42.74%	0.5766
HbA$_{1c}$ (%)					
HbA$_{1c}$ >7	37	25.87%	52	41.94%	0.0057
HbA$_{1c}$ (missing)	59	41.26%	35	28.23%	0.025
Fasting glucose (mg/dl)					
Fasting glucose >130	25	17.48%	17	13.71%	0.3961
Fasting glucose (missing)	83	58.04%	67	54.03%	0.5115

(*Continued*)

Table 5 (*Continued*)

	Early insulin initiation (5 years or less) n = 143		Late insulin initiation (6 years or more) n = 124		*P*-value
	n	%	n	%	
Satisfaction with treatment					
Very/extremely satisfied with treatment	80	56.74%	66	53.23%	0.5675
Very/extremely dissatisfied with treatment	20	14.18%	20	16.13%	0.661
Morisky adherence					
Compliant (MMAS = 0)	82	85.42%	69	79.31%	0.2819
Forget to take medication	11	11.46%	14	16.09%	0.3668
Careless about medication	8	8.33%	4	4.60%	0.3029
Stop when feeling better	0	0.00%	1	1.15%	N/A
Stop when feeling worse	3	3.13%	2	2.30%	0.7312

Abbreviations: BMI, body mass index; MMAS, Morisky Medication Adherence Scale; SD, standard deviation; HA, heart attack; TIA, transient ischemic attack; PCP, primary care physician.

0.96, 95% CI 0.93–0.991, *P* = 0.0108), and greater patient adherence (OR 1.82, 95% CI 1.015–3.251, *P* = 0.0445).

Predictors of adherence to all types of treatment

Using the MMAS (MMAS = 0), the average age of type 2 diabetes patients adherent to therapy (n = 385) was higher than that of those nonadherent to therapy (n = 121, 60.72 years versus 57.01 years, respectively, *P* = 0.0008, Table 9). The adherent patients were older at diagnosis (47.85 years versus 45.28 years, *P* = 0.0209), while the adherent group was also more likely to be female than the nonadherent group (36.88% versus 26.45%, *P* = 0.0282). Socioeconomically, the adherent group was more likely to have an income of €20,000 to <€50,000 (55.84% versus 43.80%, *P* = 0.0214), as well as being less likely to be employed (23.38% versus 36.36%, *P* = 0.0087), and were more frequently using insulin (39.48% versus 26.45%, *P* = 0.0066). In terms of clinical characteristics, the adherent group was less likely to drink

alcohol (*P* = 0.0365), had significantly more myocardial infarction (*P* = 0.0473), and had more macular edema complications (*P* = 0.0005). They were more frequently followed up by an endocrinologist or diabetologist (47.53% versus 34.71%, *P* = 0.0118). We did not see any difference in terms of control of diabetes.

A logistic regression showed two significant factors of adherence, ie, older age (OR 1.04, 95% CI 1.011–1.071, *P* = 0.0075, Table 10) and macular edema or diabetic retinopathy (OR 4.282, 95% CI 1.171–15.659, *P* = 0.0279). Conversely, currently drinking alcohol (OR 0.559, 95% CI 0.319–0.982, *P* = 0.0429), and HbA_{1c} >7% (OR 0.551, 95% CI 0.307–0.989, *P* = 0.0458) were significant predictors of nonadherence.

Insulin did not appear to be a determining factor of adherence when insulin users were compared with all users of oral bitherapy or tritherapy. However, as shown in Table 10, logistic regression comparing insulin users with uncontrolled oral bitherapy and tritherapy users (n = 256) showed that insulin

Table 6 Statistically significant factors influencing early insulin initiation

Parameter	Estimate	OR	95% LCL for OR	95% UCL for OR	SE	Chi-square	*P*-value
Influencing early insulin initiation versus late initiation (median split = 5, n = 265)							
Age at diagnosis	0.0309	1.031	1.005	1.059	0.0132	5.4509	0.0196
Income: €20,000 to <€50,000	−0.795	0.452	0.239	0.856	0.3259	5.944	0.0148
Currently smoking	0.9308	2.537	1.165	5.524	0.3971	5.496	0.0191
HbA_{1c} >7%	−0.6	0.549	0.28	1.076	0.3436	3.0503	0.0807
Influencing early insulin initiation versus uncontrolled bitherapy or tritherapy (n = 245)							
Income: €20,000 to <€50,000	−0.825	0.438	0.195	0.985	0.4133	3.9838	0.0459
Income: ≥€50,000	−1.347	0.26	0.072	0.94	0.6556	4.2236	0.0399
Prescribing physician: GP	−2.292	0.101	0.05	0.204	0.3577	41.059	<0.0001

Abbreviations: OR, odds ratio; LCL, lower confidence limit; UCL, upper confidence limit; SE, standard error; GP, general practitioner.

Table 7 Analyzed population: all controlled insulin/bitherapy or tritherapy users versus uncontrolled insulin/bitherapy or tritherapy users (excluding missing HbA$_{1c}$ level)

	All controlled insulin/ bi- or tritherapy users n = 224		Uncontrolled insulin/ bi- or tritherapy users (excluding missing HbA$_{1c}$ level) n = 208		*P*-value
	n	%	n	%	
Age (mean, SD)	60.93	10.5	59.54	9.16	0.1413
Age at diagnosis	48.16	11.57	45.38	10.92	0.0109
Age at insulin initiation (only insulin users)	50.72	15.23	51.17	12.03	0.8273
Years diagnosed	12.95	9.48	14.09	8.81	0.2009
Therapy					
Bi/tri oral therapy users	137	61.16%	105	50.48%	0.0254
Insulin users	87	38.84%	103	49.52%	0.0254
Sex					
Male	147	65.63%	141	67.79%	0.634
Female	77	34.38%	67	32.21%	0.634
Currently employed	51	22.77%	64	30.77%	0.0609
Household income					
<20,000€	56	25.00%	50	24.04%	0.8167
20,000€ to <50,000€	119	53.13%	116	55.77%	0.5819
50,000€ or more	36	16.07%	25	12.02%	0.2252
Decline to answer	13	5.80%	17	8.17%	0.3364
College education	77	34.38%	66	31.73%	0.5598
BMI					
Underweight	1	0.45%	0	0.00%	N/A
Normal weight	23	10.27%	28	13.46%	0.3066
Overweight	90	40.18%	80	38.46%	0.7155
Obese	105	46.88%	96	46.15%	0.8808
Decline to answer	5	2.23%	4	1.92%	0.822
Health behaviors					
Currently drink	175	78.13%	152	73.08%	0.2232
Currently smoke	29	12.95%	36	17.31%	0.2076
Regularly exercise	137	61.16%	109	52.40%	0.0665
Charlson comorbidity index (mean, SD)	0.38	0.91	0.44	0.87	0.4965
Comorbidities					
Depression	25	11.16%	25	12.02%	0.7811
Myocardial infarction	15	6.70%	10	4.81%	0.3988
Stroke	6	2.68%	10	4.81%	0.2469
TIA	2	0.89%	4	1.92%	0.3676
Congestive heart failure	3	1.34%	7	3.37%	0.1686
Hypertension	106	47.32%	95	45.67%	0.7319
Angina	28	12.50%	17	8.17%	0.1388
Arrhythmia	11	4.91%	18	8.65%	0.124
Prescribing physician					
PCP	104	46.43%	95	45.67%	0.8751
Endocrinologist/diabetologist	117	52.23%	112	53.85%	0.7374
Nurse practitioner/physician assistant	0	0.00%	0	0.00%	N/A
Other	3	1.34%	1	0.48%	0.3442
Agree/strongly agree to being afraid of needles	21	9.38%	22	10.58%	0.6778
Microvascular complications					
Macular edema	14	6.25%	30	14.42%	0.0055
Neuropathic pain	26	11.61%	33	15.87%	0.2003
Kidney damage	10	4.46%	16	7.69%	0.1628
End organ damage (2010, 2011 only)	7	3.70%	5	3.38%	0.8725
Foot ulcer	6	2.68%	11	5.29%	0.1685
At least one microvascular complication	45	20.09%	70	33.65%	0.0015

(*Continued*)

Table 7 (*Continued*)

	All controlled insulin/ bi- or tritherapy users n = 224		Uncontrolled insulin/ bi- or tritherapy users (excluding missing Hba$_{1c}$ level) n = 208		*P*-value
	n	%	n	%	
At least one complication (TIA, stroke, HA, or microvascular complication)	54	24.11%	81	38.94%	0.0009
HbA$_{1c}$ (%)					
HbA$_{1c}$ >7	0	0.00%	167	80.29%	N/A
HbA$_{1c}$ (missing)	0	0.00%	41	19.71%	N/A
Fasting glucose (mg/dl)					
Fasting glucose >130	19	8.48%	68	32.69%	<0.0001
Fasting glucose (missing)	130	58.04%	86	41.35%	0.0005
Satisfaction with treatment					
Very/extremely satisfied with treatment	146	65.18%	97	46.63%	<0.0001
Very/extremely dissatisfied with treatment	31	13.84%	24	11.54%	0.4728
Morisky adherence (2010, 2011 only)					
Compliant (MMAS = 0)	154	81.48%	108	72.97%	0.0667
Forget to take medication	30	15.87%	37	25.00%	0.0411
Careless about medication	14	7.41%	12	8.11%	0.8123
Stop when feeling better	2	1.06%	0	0.00%	N/A
Stop when feeling worse	4	2.12%	5	3.38%	0.4885

Abbreviations: BMI, body mass index; MMAS, Morisky Medication Adherence Scale; SD, standard deviation; HA, heart attack; TIA, transient ischemic attack; PCP, primary care physician.

users had 3.0 times greater odds of being adherent (OR 2.983, 95% CI 1.37–6.495, *P* = 0.0059), with even greater odds when early insulin users were considered (3.337, 95% CI 1.295–8.595, *P* = 0.0126).

Impact of insulin on quality of life

Linear regression models were used to assess the impact of insulin, early insulin initiation, and short (≤5 years) insulin duration versus uncontrolled bitherapy and tritherapy users on MCS and PCS scores. Table 11 summarizes the adjusted means for MCS and PCS. Overall, no significant difference was observed between the two groups on the MCS (44.182 versus 45.832), and PCS (39.611 versus 40.093) scores. However, one must note the significant difference (*P* = 0.0304) on the MCS in the early insulin initiation subgroup, which can be explained by the eventual

complications and negative perception of insulin as a last resort treatment. Indeed, there were no significant differences between the early insulin patients with no complications versus patients uncontrolled by bitherapy or tritherapy. As shown in Figure 1, when the presence or absence of complications were considered, whatever the treatment, the presence of complications had a negative impact on both MCS (42.66 versus 47.36, *P* < 0.0001) and PCS (34.32 versus 43.48, *P* < 0.0001).

Analysis of MCS and PCS data based on duration of insulin therapy (<3 years, 3–5 years, 6–10 years, ≥11 years) allowed observation of the stability of quality of life scores on the two dimensions, with the only significant difference on physical health decreasing after 11 years and more of treatment, compared with <3 years in relation to the appearance of chronic complications (Figure 2).

Table 8 Statistically significant factors influencing control of diabetes: all controlled insulin/bitherapy or tritherapy users versus uncontrolled insulin/bitherapy or tritherapy users (n = 336)

| Parameter	Estimate	OR	95% LCL for OR	95% UCL for OR	SE	Chi-square	*P*-value
Duration of type 2 diabetes	−0.041	0.96	0.93	0.991	0.0161	6.4939	0.0108
Compliant	0.5967	1.816	1.015	3.251	0.297	4.0362	0.0445
Very/extremely satisfied with treatment	0.934	2.545	1.556	4.16	0.2508	13.8687	0.0002

Note: Excludes respondents who did not know their HbA$_{1c}$ level.
Abbreviations: OR, odds ratio; LCL, lower confidence limit; UCL, upper confidence limit; SE, standard error.

Table 9 Analyzed population: all adherent insulin/bitherapy or tritherapy users versus all nonadherent insulin/bitherapy or tritherapy users

	Non-compliant – total treatment insulin/ bi- or tritherapy users n = 121		Compliant – total treatment insulin/ bi- or tritherapy users n = 385		P-value
	n	%	n	%	
Age (mean, SD)	57.01	10.75	60.72	9.27	0.0008
Age at diagnosis	45.28	10.58	47.85	10.68	0.0209
Age at insulin initiation (only insulin users)	50.47	11.82	52.51	12.02	0.3813
Years diagnosed	11.73	8.2	12.97	8.82	0.1564
Therapy					
Bi/tri oral therapy users	89	73.55%	233	60.52%	0.0066
Insulin users	32	26.45%	152	39.48%	0.0066
Sex					
Male	89	73.55%	243	63.12%	0.0282
Female	32	26.45%	142	36.88%	0.0282
Currently employed	44	36.36%	90	23.38%	0.0087
Household income					
<20,000€	34	28.10%	99	25.71%	0.6091
20,000€ to <50,000€	53	43.80%	215	55.84%	0.0214
50,000€ or more	19	15.70%	36	9.35%	0.082
Decline to answer	15	12.40%	35	9.09%	0.3232
College education	47	38.84%	141	36.62%	0.6619
BMI					
Underweight	0	0.00%	1	0.26%	N/A
Normal weight	14	11.57%	38	9.87%	0.6051
Overweight	41	33.88%	145	37.66%	0.4475
Obese	64	52.89%	186	48.31%	0.3801
Decline to answer	2	1.65%	15	3.90%	0.1428
Health behaviors					
Currently drink	96	79.34%	270	70.13%	0.0365
Currently smoke	24	19.83%	60	15.58%	0.298
Regularly exercise	59	48.76%	202	52.47%	0.4777
Charlson comorbidity index (mean, SD)	0.29	0.72	0.36	0.72	0.3776
Comorbidities					
Depression	10	8.26%	50	12.99%	0.1218
Myocardial infarction	3	2.48%	24	6.23%	0.0473
Stroke	3	2.48%	15	3.90%	0.4124
TIA	2	1.65%	3	0.78%	0.4831
Congestive heart failure	0	0.00%	10	2.60%	N/A
Hypertension	58	47.93%	164	42.60%	0.3059
Angina	21	17.36%	44	11.43%	0.1217
Arrhythmia	4	3.31%	28	7.27%	0.0606
Prescribing physician					
PCP	79	65.29%	199	51.69%	0.0077
Endocrinologist/diabetologist	42	34.71%	183	47.53%	0.0118
Nurse practitioner/physician assistant	0	0.00%	0	0.00%	N/A
Other	0	0.00%	3	0.78%	N/A
Agree/strongly agree to being afraid of needles	16	13.22%	34	8.83%	0.1989
Microvascular complications					
Macular edema	3	2.48%	38	9.87%	0.0005
Neuropathic pain	16	13.22%	45	11.69%	0.6605
Kidney damage	4	3.31%	19	4.94%	0.4083
End organ damage (2010, 2011 only)	4	3.31%	15	3.90%	0.7566
Foot ulcer	4	3.31%	15	3.90%	0.7566
At least one microvascular complication	25	20.66%	93	24.16%	0.4154
At least one complication (TIA, stroke, HA, or microvascular complication)	30	24.79%	110	28.57%	0.4078

(*Continued*)

Table 9 (*Continued*)

	Non-compliant – total treatment insulin/ bi- or tritherapy users n = 121		Compliant – total treatment insulin/ bi- or tritherapy users n = 385		*P*-value
	n	%	n	%	
HbA$_{1c}$ (%)					
HbA$_{1c}$ >7	39	32.23%	104	27.01%	0.2802
HbA$_{1c}$ (missing)	47	38.84%	127	32.99%	0.247
Fasting glucose (mg/dl)					
Fasting glucose >130	5	4.13%	15	3.90%	0.9089
Fasting glucose (missing)	80	66.12%	243	63.12%	0.546
Satisfaction with treatment					
Very/extremely satisfied with treatment	56	46.67%	218	56.77%	0.0545
Very/extremely dissatisfied with treatment	13	10.83%	55	14.32%	0.2998

Abbreviations: BMI, body mass index; SD, standard deviation; HA, heart attack; TIA, transient ischemic attack; PCP, primary care physician.

Table 10 Statistically significant factors influencing adherence to diabetes medication: adherent versus nonadherent users

Parameter	Estimate	OR	95% LCL for OR	95% UCL for OR	SE	Chi-square	*P*-value
All insulin/bitherapy or tritherapy users (n = 503)							
Age at diagnosis	0.0396	1.04	1.011	1.071	0.0148	7.1376	0.0075
Currently drinking alcohol	−0.5813	0.559	0.319	0.982	0.2871	4.0984	0.0429
Macular edema or diabetic retinopathy	1.4543	4.282	1.171	15.659	0.6616	4.8316	0.0279
HbA$_{1c}$ >7%	−0.5954	0.551	0.307	0.989	0.2981	3.9884	0.0458
All insulin users and uncontrolled bitherapy or tritherapy users (n = 256)							
All insulin versus uncontrolled bitherapy or tritherapy	1.0931	2.983	1.37	6.495	0.3969	7.5828	0.0059
Macular edema or diabetic retinopathy	1.8705	6.492	1.301	32.381	0.8199	5.2042	0.0225
Very/extremely satisfied with treatment	0.7141	2.042	1.043	3.998	0.3427	4.3427	0.0372
Early insulin initiation and uncontrolled bitherapy or tritherapy users (n = 169)							
Early insulin versus uncontrolled bitherapy or tritherapy	1.205	3.337	1.295	8.595	0.4828	6.2298	0.0126

Abbreviations: OR, odds ratio; LCL, lower confidence limit; UCL, upper confidence limit; SE, standard error.

Table 11 Summary of adjusted means for MCS and PCS scores on bitherapy or tritherapy

	All insulin users	Uncontrolled bitherapy or tritherapy users	*P*-value
Adjusted means			
Mental component summary	44.18	45.83	0.2317
Physical component summary	39.61	40.09	0.6686
	Early insulin initiation (≤5 years)	**Uncontrolled bitherapy or tritherapy users**	
Mental component summary	**42.85**	**46.37**	**0.0304**
Physical component summary	39.49	40.35	0.5232
	Early insulin initiation (≤5 years) with no complications	**Uncontrolled bitherapy or tritherapy users**	
Mental component summary	44.88	46.71	0.2945
Physical component summary	42.94	42.03	0.5748

Note: Data in bold is significant.
Abbreviations: MCS, Mental Component Summary; PCS, Physical Component Summary.

Figure 1 Mean MCS and PCS scores by type 2 diabetes complications (insulin users).
Note: *$P < 0.0001$ for no complications versus complications.
**Abbreviations:** MCS, Mental Component Summary; PCS, Physical Component Summary.

Also, as post hoc analyses, type 2 diabetes quality of life scores were compared with other disease conditions. Figure 3 shows that patients with type 2 diabetes have lower mental health scores (MCS = 45.86) relative to the average person, but higher levels of mental health than people diagnosed with depression, and similar scores relative to patients with metabolic syndrome, allergic rhinitis, or hepatitis C. Patients with type 2 diabetes had lower levels of physical health (PCS = 42.32) relative to the average person and people suffering from allergic rhinitis and depression, but very similar levels of physical health relative to patients with hepatitis C. Also, quite surprisingly, they had higher levels

of physical health compared with those having metabolic syndrome.

Discussion
Determinants of insulin prescription
In this study, factors determining insulin prescription in multivariable analysis consisted of lower age at type 2 diabetes diagnosis, the presence of retinopathy, neuropathic pain, being treated by a specialist, and lower (<€50,000 per annum) income. Factors determining early insulin prescription in the course of the disease, as compared with late insulin prescription, were of younger age at diagnosis

Figure 2 Mean MCS (left) and PCS scores (right): comparison of early versus late insulin initiation.
Abbreviations: MCS, Mental Component Summary; PCS, Physical Component Summary.

Figure 3 PCS and MCS scores for common conditions in Europe.
Abbreviations: MCS, Mental Component Summary; PCS, Physical Component Summary; T2D, type 2 diabetes.

and had a lower income. When the factors determining early insulin prescription in the course of the disease were analyzed as compared with uncontrolled oral therapy, lower income and being treated by a specialist were observed to be significant.

It is not surprising to observe that patients with severe complications are more often treated with insulin; the effect of an early diabetes onset may be explained by the presence of late autoimmune diabetes among the patients in the study, with up to 10% of patients diagnosed with type 2 diabetes found to have anti-glutamic acid decarboxylase antibodies.[26] The higher frequency of specialist care in insulin treated patients must be interpreted with caution. It does not mean that general practitioners are reluctant to prescribe insulin. They may refer the patient to the specialist when they appropriately estimate that insulin should be prescribed: incidentally, this may explain why, in one study, clinical inertia concerning insulin prescription was found to be more frequent among general practitioners than among specialists.[14]

The independent effect of patients' income observed herein is more original: our data suggest that patients with a lower income are more frequently treated by insulin. While the deleterious effect of social deprivation on patient adherence is known,[27] whether low income leads to an increased risk of doctors' clinical inertia is harder to determine. For instance, one study showed that patients of low socioeconomic class had diabetes more often and were able to achieve treatment targets less often, but in fact had indicators of good practice more often, ie, measurement of HbA_{1c}, microalbuminuria, eye examination, treatment by insulin in insufficient control of diabetes.[28] However, a more recent study did not show evidence of a language barrier effect on intensification of therapy in patients with type 2 diabetes imbalance, but a low level of income was clearly associated with less treatment intensification.[29]

Predictors of control of diabetes

In the bivariate analysis, we observed classical determinants of diabetes control, such as diabetes duration, adherence to therapy (the effect of adherence on metabolic control, hypercholesterolemia, and hypertension is also well substantiated),[30–33] and, as expected, we observed an association of good control with less frequency of diabetic complications.

The strong effect of satisfaction towards treatment is more puzzling: not the fact that controlled patients are more frequently satisfied by their treatment, which seems to hold true. But the fact that in the multivariable analysis this determinant had by far the strongest link with diabetes control, suggesting that other factors (eg, dosage, number of required treatments per day) could be influencing this particular variable.

Predictors of patient adherence

This study confirms the known determinants of adherence observed in the multivariable analysis, ie, older age,[34–37] abstinence from drinking,[38] metabolic control,[30,31,39] and the presence of complications.[37] Surprisingly, we did not observe any association between nonsmoking and adherence, which was shown in some studies.[40–43] In bivariate analysis, we observed that adherent respondents were less likely to be employed. This was also observed in the recent French ENTRED (Medication Adherence in Type 2 Diabetes) study.[37] In our

study, adherent patients reported lower income status, while in the ENTRED study,[37] financial difficulties were associated with a low adherence rate, as in a Swedish study.[27] The fact that, in our study, lower income was associated with good adherence is consistent with a Canadian study.[44] The fact that the same findings were observed in France, where diabetic drugs are paid by the social security program, suggests that this effect may not be due to what was observed in Canada (the effect of copayment).

In our study, insulin adherence was better in patients treated with insulin than in those treated with oral antidiabetic medication, especially in the case of early insulin prescription. Indeed, insulin users had 3.0 times greater odds of being adherent compared with uncontrolled oral bitherapy or tritherapy users (OR 2.983, $P = 0.0059$). Interestingly, the fact that adherence may be better with injections was proposed as an argument to favor injectable rather than oral penicillin in children with impaired splenic function,[45] and it is also a concern when considering adherence to cancer therapy.[46] This better adherence to injectable therapy, observed in our study, is in contradiction with the general concern of physicians concerning patient adherence as a cause of psychological insulin resistance.[47]

Effect of treatment with insulin on quality of life

Overall, no significant difference was observed between insulin users and uncontrolled bitherapy or tritherapy users concerning MCS and PCS scores. Quality of life, both physical and mental, was therefore not altered compared with that in patients uncontrolled on bitherapy or tritherapy. Physical health scores decreased after 11 years of diabetes therapy, possibly an effect of the appearance of chronic complications. The lower MCS score in the early insulin initiation subgroup may also be explained by the eventual presence of complications, which were well analyzed in this study (Figure 1). Indeed, there were no significant differences for the early insulin patients with no complications versus patients uncontrolled by bitherapy or tritherapy.

In this context of quality of life, reflecting the burden of the disease, it was interesting to compare the European data concerning type 2 diabetes with those of other high-prevalence chronic diseases. For this comparison, previous European NHWS studies were prioritized, because the methodology and measures were the same, thus providing the most suitable and relevant basis for comparison with diabetes in the current study. Comparison of scores (Figure 3) shows that the MCS and PCS scores for patients with type 2 diabetes

are comparable across other conditions, and patients with type 2 diabetes have relative lower scores than the general population.

Although this study has some weak points, many of the findings are consistent with those reported in the literature. The first limitation is the relatively small number of patients as compared with other studies addressing specific issues, such as patient adherence based on refill evaluation, allowing analysis of much larger populations. Thus, the small sample sizes in the current study precluded the ability to conduct multivariable analyses for specific delays or duration of treatment, or to generalize broadly from the current data. Future research should adjust for possible confounds with larger samples and multivariable analysis.

Secondly, the Internet survey methodology may have introduced bias, explaining for instance the unexpected high male to female ratio observed in this study. The Internet survey was a real limitation in France in 2008, with lower Internet penetration in the female population explaining the overestimation of males in the diabetic population, as in 2010 this bias was less important with a rate of 59% of males much closer to the normal rate of 54% in type 2 diabetes.[37] Also, due to the self-report nature of the current study, no verification of diagnoses, treatment, fasting glucose, HbA_{1c} level or disease complications was made.

Third, cross-sectional data provide a one-time snapshot of the relationships between study variables. They can suggest directions for further research, but definite claims cannot be made regarding causal relationships among domains (eg, earlier insulin initiation and quality of life or adherence). However, the relevance of this data is strong because of the comparable methodology; 3 years of data can be pulled and a larger sample size is achievable, the patients reported are looking at many different measures using validated scales (the MMAS and SF-12v2) and even more are looking at treatment satisfaction, all these dimensions that can only have been caught from the patient perspective.

Conclusion

With these limitations in mind, the current study contributes to the growing literature documenting the burden and health effects associated with insulin treatment. There may be a rationale for prescribing insulin earlier than what is done with the current treatment paradigm.[5] Recently, the effect of introducing insulin early in the course of the disease was reported in the ORIGIN (Outcome Reduction with Initial Glargine Intervention insuliN glargine therapy) study.[48] The effect on prevention of mortality was neutral in this study.

However, early insulin initiation was shown to be safe, leading to a modest increase in body weight and in the rate of severe hypoglycemia, and was reassuring concerning the risk of cancer. There was a reduction in diabetes incidence in individuals having only prediabetes at entry to the study. Thus, given the potential impact of prescribing insulin earlier, the current paper provides important information regarding the experience of insulin users in France. Finally, the main finding of our study was an unexpected improvement in adherence among insulin-treated patients, and the absence of a deleterious effect on quality of life in patients with no complications. This may represent an argument to fight against psychological insulin resistance.

Acknowledgments

Disclosure

References

1. Hu FB. Globalization of diabetes. The role of diet, lifestyle, and genes. *Diabetes Care*. 2011;34:1249–1257.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*. 2008;359:1577–1589.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*. 2012;55:1577–1596.
4. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. *Ann Intern Med*. 2011;154:554–559.
5. Hsu WC. Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. *South Med J*. 2009;102:67–76.
6. Turner RC, Holman RR. Insulin rather than glucose homeostasis in the pathophysiology of diabetes. *Lancet*. 1976;1:1272–1274.
7. Le Roith D, Fonseca V, Vinik A. Metabolic memory in diabetes – focus on insulin. *Diabetes Metab Res Rev*. 2005;21:85–90.
8. Leslie CA, Satin-Rapaport W, Matheson D, et al. Psychological insulin resistance: a missed diagnosis. *Diabetes Spectr*. 1994;7:52–57.
9. Phillips LS, Branch WT Jr, Cook CB, et al. Clinical inertia. *Ann Intern Med*. 2001;135:825–834.
10. Balkau B, Bouée S, Avignon A et al. Type 2 diabetes treatment intensification in general practice in France in 2008-2009: The DIAttitude study. *Diabetes Metab*. 2012;38: S29–S35.
11. Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. *Am J Manag Care*. 2003;9:213–217.
12. El-kebbi IM, Ziemer DC, Gallina DL, Dunbar V, Phillips LS. Diabetes in urban African-Americans. Identification of barriers to provider adherence to management protocols. *Diabetes Care*. 1999;22: 1617–1620.
13. Harris SB, Kapor J, Lank CN, Willan AR, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. *Can Fam Physician*. 2010;56:e418–e424.
14. Shah BR, Hux JE, Laupacis A, Zinman B, Van Walraven C. Clinical inertia in response to inadequate glycemic control do specialists differ from primary care physicians? *Diabetes Care*. 2005;28:600–606.
15. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. *QJM*. 2000;93:369–374.
16. Peyrot M, Rubin RR, Lauritzen T, et al; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. *Diabetes Care*. 2005;28:2673–2679.
17. Peyrot M, Rubin RR, Khuntic K, et al. Addressing barriers to initiation of insulin in patients with type 2 diabetes. *Prim Care Diabetes*. 2010;4 Suppl 1:11–18.
18. Phillips P. Type 2 diabetes – failure, blame and guilt in the adoption of insulin therapy. *Rev Diabetic Stud*. 2005;2:35–39.
19. Woudenberg YJ, Lucas C, Latour C, Scholte op Reimer WJ. Acceptance of insulin therapy: a long shot? Psychological insulin resistance in primary care. *Diabet Med*. 2012;29:796–802.
20. Campbell RK. Recommendations for improving adherence to type 2 diabetes mellitus therapy-focus on optimizing insulin-based therapy. *Am J Manag Care*. 2012;18(3):S55–61.
21. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. *Diabetes Obes Metab*. 2012;9999:9999.
22. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. *Diabetes Care*. 2010;33:240–245.
23. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. *J Gen Intern Med*. 2008;23:588–594.
24. Ware JE, Kosinski M, Turner-Bowker DM, et al. *How to Score Version 2 of the SF-12 Health Survey* (with a supplement documenting version 1). Lincoln, RI: Quality Metric; 2002.
25. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care*. 1986;24:67–74.
26. Desai M, Clark A. Autoimmune diabetes in adults: lessons from the UKPDS. *Diabet Med*. 2008;Suppl 2:30–34.
27. Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G. Socioeconomic disadvantage and primary non-adherence with medication in Sweden. *Int J Qual Health Care*. 2007;19:134–140.
28. Jotkowitz AB, Rabinowitz G, Raskin Segal A, Weitzman R, Epstein L, Porath A. Do patients with diabetes and low socioeconomic status receive less care and have worse outcomes? A national study. *Am J Med*. 2006;119:665–669.
29. Duru OK, Bilik D, McEwen LN, et al. Primary language, income and the intensification of anti-glycemic medications in managed care: the (TRIAD) study. *J Gen Intern Med*. 2011;26:505–511.

30. Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a Diabetes Disease Management Program. *J Manag Care Pharm*. 2006;12:466–471.

31. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. *Am J Manag Care*. 2008;14:71–75.

32. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. *Diabetes Care*. 2005;28:595–599.

33. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive mono-therapy in 13 managed care organizations. *J Manag Care Pharm*. 2006;12:239–245.

34. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. *Pharmacotherapy*. 2008;28:437–443.

35. Lee R, Taira DA. Adherence to oral hypoglycemic agents in Hawaii. *Prev Chronic Dis*. 2005;2:A09.

36. Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. *Curr Med Res Opin*. 2010;26:231–238.

37. Tiv M, Viel JF, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED Study 2007, a French population-based study. *PLoS One*. 2012;7:e32412.

38. Ahmed AT, Karter AJ, Liu J. Alcohol consumption is inversely associated with adherence to diabetes self-care behaviours. *Diabet Med*. 2006;23:795–802.

39. Reach G. Obedience and motivation as mechanisms for adherence to medication: a study in obese type 2 diabetic patients. *Patient Prefer Adherence*. 2011;5:523–531.

40. Jiménez-García R, Esteban-Hernández J, Hernández-Barrera V, et al. Clustering of unhealthy lifestyle behaviors is associated with nonadherence to clinical preventive recommendations among adults with diabetes. *J Diabetes Complications*. 2011;25:107–113.

41. Chiu CJ, Wray LA. Factors predicting glycemic control in middle-aged and older adults with type 2 diabetes. *Prev Chronic Dis*. 2010;7:A08.

42. Toljamo M, Hentinen M. Adherence to self-care and glycaemic control among people with insulin-dependent diabetes mellitus. *J Adv Nurs*. 2001;34:780–786.

43. Karter AJ, Ferrara A, Darbinian JA, Ackerson LM, Selby JV. Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. *Diabetes Care*. 2000;23: 477–483.

44. Grégoire JP, Moisan J, Guibert R, et al. Determinants of discontinuation of new courses of antihypertensive medications. *J Clin Epidemiol*. 2002;55:728–735.

45. Babiker MA. Compliance with penicillin prophylaxis by children with impaired splenic function. *Trop Geogr Med*. 1986;38:119–122.

46. Partridge AH. Non-adherence to endocrine therapy for breast cancer. *Ann Oncol*. 2006;17:183–184.

47. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. *J Diabetes Complications*. 2007;21:220–226.

48. ORIGIN Trial Investigators; Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012;367:319–328.